Nabriva Therapeutics AG – (NASDAQ:NBRV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday.
According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “
Several other equities analysts also recently weighed in on NBRV. Wedbush reaffirmed an “outperform” rating and set a $17.00 price target on shares of Nabriva Therapeutics AG – in a report on Tuesday, August 9th. HC Wainwright initiated coverage on shares of Nabriva Therapeutics AG – in a report on Thursday, September 8th. They set a “buy” rating and a $16.00 price target on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $15.93.
Shares of Nabriva Therapeutics AG – (NASDAQ:NBRV) opened at 7.24 on Friday. Nabriva Therapeutics AG – has a 12 month low of $6.61 and a 12 month high of $10.69. The firm’s 50-day moving average is $7.60 and its 200 day moving average is $8.05. The stock’s market cap is $153.90 million.
Nabriva Therapeutics AG – (NASDAQ:NBRV) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($6.25) by $5.75. On average, equities analysts predict that Nabriva Therapeutics AG – will post ($1.93) EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in the company. Jackson Park Capital LLC bought a new position in Nabriva Therapeutics AG – during the second quarter valued at approximately $195,000. Opaleye Management Inc. boosted its stake in shares of Nabriva Therapeutics AG – by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock valued at $2,453,000 after buying an additional 53,800 shares in the last quarter. Finally, Vivo Capital LLC acquired a new stake in shares of Nabriva Therapeutics AG – during the first quarter valued at $28,239,000.
Nabriva Therapeutics AG – Company Profile
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).
Receive News & Ratings for Nabriva Therapeutics AG - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG - and related companies with MarketBeat.com's FREE daily email newsletter.